Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Mutations in four genes (α-synuclein, UCH-L1, parkin, and DJ-1) have been identified in familial Parkinson disease (PD). Recently, two mutations in the 5′-region of the orphan nuclear receptor Nurr1 (NR4A2) gene have been found in 10% of familial PD cases, of which one-third were of German ancestry.1 Furthermore, a polymorphism in intron 6 of the Nurr1 gene was associated with PD in two independent studies.2,3⇓
The transcription factor Nurr1 is highly expressed in dopaminergic cells of the substantia nigra. Deficiency of Nurr1 in mice leads to a lack of dopaminergic neurons.4 Based on these data, we explored the 7048G7049 polymorphism in intron 6 as well as two novel sequence variations, −291Tdel and −245T→G, in exon 1 of Nurr1 in a large cohort of PD patients.
For analysis of the 7048G7049 polymorphism, 424 PD patients were investigated (mean age at disease onset 55.4 ± 12.1 years; 54.6% male, 45.4% female; with 55 patients [13.0%] having a positive family history). For analysis of the two novel sequence variations, −291Tdel and −245T→G, …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson diseaseIs there a gender effect?A. Orr-Urtreger, C. Shifrin, U. Rozovski et al.Neurology, October 15, 2007 -
Article
The scientific and clinical basis for the treatment of Parkinson disease (2009)C. Warren Olanow, Matthew B. Stern, Kapil Sethi et al.Neurology, May 26, 2009 -
Articles
Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson’s diseaseD.K. Simon, R. Mayeux, K. Marder et al.Neurology, February 08, 2000 -
Articles
Familial aggregation of Parkinson’s diseaseA population-based case-control study in EuropeA. Elbaz, F. Grigoletto, M. Baldereschi et al.Neurology, June 01, 1999